zusduri
Generic: mitomycin·Code: UGN-102
zusduri: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| UroGen Pharma Ltd. (URGN) | Approved |
FDA Decisions
Approval1 INDICATIONS AND USAGE ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI is an alkylating drug indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ( 1 )(URGN)
Frequently asked questions
Who is developing zusduri?
zusduri is being developed by UroGen Pharma Ltd..
What is zusduri's latest FDA decision?
The most recent tracked FDA decision for zusduri is Approval for 1 INDICATIONS AND USAGE ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI is an alkylating drug indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ( 1 ), dated June 12, 2025.
Get deeper analysis on zusduri
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis